In this study, we examined the in vivo and in vitro effect of the combination regimen of PTX and the specific PXR antagonist SPA70 on PTX-sensitive and PTX-resistant NSCLC subline A549 and H460. This evidence concerns the gene NR1I2 and non-small cell lung carcinoma.